TRDA - Entrada Therapeutics, Inc. Price-to-Projected Revenue Ratio

Entrada Therapeutics (TRDA) is pursuing expansion into orphan disease therapies by scaling its EEV platform. The forward P/S ratio on GURU.Markets reflects the asset's dynamics, where the value of 50.20 corresponds to the current metric. While stability is based on B2B partnerships, stringent FDA oversight and a high cash burn rate create significant financial risks during the early stages of development.

Entrada Therapeutics Inc. - TRDA Projected Price to Revenue (period 05/21/2023 - 11/14/2026)

TRDA (Entrada Therapeutics, Inc): analytical breakdowns and indicator data

- market price and analyst price targets:

Price Chart Entrada Therapeutics, Inc.|TRDA - Price Target Chart

- market capitalization statistics:

Market Value Entrada Therapeutics, Inc|TRDA - Total Enterprise Value

- book value of equity indicators:

Book Value per Share Entrada Therapeutics|TRDA - Book Value of Business|Market Cap to Net Assets Ratio entradatx.com|TRDA - Company Assets

- debt and liquidity data:

- financial results and valuation multiples details:

TRDA - Net Profit|Projected Future Earnings Entrada Therapeutics|TRDA - Price to Earnings Multiple|Forward P/E Multiple Entrada|TRDA - PEG Multiple|Enterprise Value to EBITDA Ratio Entrada Therapeutics, Inc|TRDA - Income before deduction of interest, taxes and amortization|Net earnings per share for the last 12 months Entrada Therapeutics|TRDA - Earnings per share for the last four quarters|Quarterly EPS earnings growth entradatx.com|TRDA - Earnings per share increase in current year|Earnings growth forecast for next year Entrada Therapeutics

- revenue and sales proceeds data:

TRDA - Company Total Revenue|Company Projected Revenue Entrada Therapeutics, Inc.|TRDA - Market Capitalization-to-Revenue Ratio|Forward P/S Multiple Entrada Therapeutics, Inc

Fundamental company valuation:Entrada Therapeutics, Inc. (TRDA)

Forward P/S assesses the market value of an asset relative to expected revenue streams, allowing investors to filter out volatility and determine the premium paid for potential growth. Given the absence of current sales for Entrada Therapeutics (TRDA), the company's modeled P/S reflects the speculative value of its B2B platform and the dependence of its capitalization on FDA regulatory decisions, thereby defining the fundamental stability of the business.

Competing companies

Price-to-Projected Revenue Ratio Jazz Pharmaceuticals plc JAZZ|Cytokinetics Inc. - Price-to-Projected Revenue Ratio|PTCT - Price-to-Projected Revenue Ratio|Market Cap to Future Revenue Ratio Scholar Rock Inc.|CNTA: Forward P/S Multiple|Projected Price to Revenue dyne-tx.com DYN|Forward Price-to-Revenue Multiple EWTX|Market Cap to Future Revenue Ratio Rapport Therapeutics Inc RAPP|Forward P/S Multiple ALMS|ZVRA - Market Cap to Future Revenue Ratio|Price-to-Projected Revenue Ratio Contineum Therapeutics, Inc. CTNM|LRMR: Market Cap to Projected Revenue|CAPR: Forward Price-to-Revenue Multiple|Channel Therapeutics Inc. - Price to Expected Revenue Ratio|medicinova.com (MNOV) - Price-to-Projected Revenue Ratio|Serina Pharma - Forward Price to Sales|BTAI (BioXcel Therapeutics) - Forward P/S Multiple|Forward P/S Multiple ProMIS|Forward P/S Multiple APUS|aeonbiopharma.com - Market Cap to Projected Revenue|Forward P/S Multiple NLSP (NLS Pharmaceutics)|Forward P/S Multiple Bionomics Ltd. BNOX|HUGE: Forward Price-to-Revenue Multiple|Forward Price to Sales RETA (reatapharma.com)